- Insulin, a vital therapy for diabetes management, is becoming increasingly crucial globally due to its role in maintaining blood glucose levels and preventing complications such as neuropathy, kidney failure, and cardiovascular disease
- The rising prevalence of diabetes, increasing healthcare awareness, and technological advancements in insulin delivery devices (such as pens, pumps, and smart systems) are driving a shift towards more patient-friendly and effective diabetes care
- North America dominated the insulin market with a revenue share of 44.6% in 2024, benefiting from high diabetes prevalence, advanced healthcare infrastructure, significant R&D investment, and robust adoption of insulin analogs and delivery devices
- Asia-Pacific is the fastest-growing region in the insulin market, with a projected CAGR of 11.8% from 2025 to 2032, driven by increasing diabetes burden, rising disposable incomes, and greater insulin awareness across China, India, Japan, and Australia
- The long acting insulin segment dominated the market, accounting for 42.7% market share in 2024, owing to its prolonged duration of action, reduced injection frequency, and high patient compliance in both Type 1 and Type 2 diabetes management
